A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

406

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunoglobulin A Nephropathy

Interventions

DRUG: sparsentan
DRUG: irbesartan
DRUG: Dapagliflozin

Sponsor

Travere Therapeutics, Inc.